Residential
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $62.90M by Medicaid between Jan 2018 and Dec 2024, across 352 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
HARBOR CITY, CA 90710
HARBOR CITY, CA 90710
33aNPI1336294040assigned 01/24/2007
33bProvider typeSubstance Abuse Rehabilitation Facility
28Total paid$62.90M
24GClaims1,691,737
24DCodes billed352
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Substance Abuse Rehabilitation Facility providers in California
Rank by total paid#1 of 28
Median peer was paid$167K
This provider vs. median376×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 157,483 | $1.55M | |
| 2019 | 226,764 | $7.24M | |
| 2020 | 212,648 | $11.41M | |
| 2021 | 241,755 | $8.88M | |
| 2022 | 253,286 | $9.76M | |
| 2023 | 293,367 | $11.46M | |
| 2024incomplete | 306,434 | $12.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 48,812 | 44,985 | $21.71M |
| G0378 | Hospital observation service, per hour | 11% | 5,758 | 3,361 | $6.91M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 8,349 | 7,948 | $6.30M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 6,819 | 6,708 | $2.18M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.9% | 1,706 | 1,638 | $1.80M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.2% | 942 | 939 | $1.38M |
| 0450 | Emergency room services | 1.7% | 24,623 | 22,018 | $1.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 4,318 | 4,248 | $998K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 6,971 | 6,769 | $680K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 3,400 | 3,348 | $640K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,309 | 10,673 | $551K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,284 | 6,175 | $535K |
340 more codes
| 76830 | Ultrasound, transvaginal | <1% | 5,836 | $501K |
| 86900 | <1% | 8,739 | $456K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 13,498 | $451K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,157 | $445K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,035 | $436K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,729 | $423K |
| 93971 | <1% | 1,887 | $407K | |
| 86885 | <1% | 6,075 | $398K | |
| 82565 | <1% | 102,822 | $380K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 989 | $369K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,879 | $361K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,872 | $361K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,670 | $347K |
| 80051 | <1% | 82,999 | $337K | |
| 0111 | <1% | 507 | $334K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,497 | $333K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,863 | $330K |
| 83880 | <1% | 15,351 | $298K | |
| 85027 | <1% | 51,329 | $283K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 212 | $271K |
| 84460 | <1% | 62,036 | $265K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,912 | $259K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 28,178 | $258K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,368 | $255K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,566 | $229K |
| 93970 | <1% | 655 | $220K | |
| 80061 | Lipid panel | <1% | 16,640 | $212K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,155 | $193K |
| 84702 | <1% | 15,537 | $187K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,810 | $182K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 729 | $173K |
| 76770 | <1% | 1,910 | $173K | |
| 82247 | <1% | 47,202 | $171K | |
| 0112 | <1% | 276 | $167K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 715 | $164K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,021 | $146K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,429 | $146K |
| 72141 | <1% | 661 | $142K | |
| 86901 | <1% | 8,746 | $142K | |
| 84075 | <1% | 39,563 | $141K | |
| 74183 | <1% | 321 | $141K | |
| 86141 | <1% | 12,299 | $140K | |
| 43775 | <1% | 26 | $136K | |
| 82728 | <1% | 10,697 | $135K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,661 | $132K |
| 76536 | <1% | 1,287 | $130K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 551 | $126K |
| 73562 | <1% | 2,127 | $121K | |
| 84520 | <1% | 64,603 | $119K | |
| 76641 | <1% | 1,259 | $119K | |
| 82947 | <1% | 60,782 | $116K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,292 | $115K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 432 | $114K |
| 83970 | <1% | 2,579 | $109K | |
| 73630 | <1% | 2,150 | $108K | |
| 86780 | <1% | 8,412 | $106K | |
| 84450 | <1% | 31,699 | $105K | |
| 85610 | <1% | 35,321 | $101K | |
| 72100 | <1% | 1,233 | $99K | |
| 70486 | <1% | 835 | $95K | |
| 73030 | <1% | 1,674 | $92K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,986 | $92K |
| 73610 | <1% | 1,765 | $87K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,368 | $82K |
| 76801 | <1% | 928 | $81K | |
| 71250 | <1% | 632 | $81K | |
| 83690 | <1% | 22,234 | $79K | |
| 81003 | <1% | 48,015 | $77K | |
| 82607 | <1% | 5,106 | $76K | |
| 83550 | <1% | 9,100 | $75K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,977 | $74K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 848 | $73K |
| 62323 | <1% | 86 | $72K | |
| 82310 | <1% | 19,269 | $72K | |
| 87505 | <1% | 760 | $70K | |
| 84484 | <1% | 20,150 | $69K | |
| 86480 | <1% | 1,067 | $68K | |
| 0637 | <1% | 74,224 | $68K | |
| 86803 | <1% | 4,732 | $62K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,657 | $59K |
| 99199 | Unlisted special service, procedure or report | <1% | 1,908 | $57K |
| 83735 | <1% | 15,393 | $55K | |
| 83520 | <1% | 3,195 | $55K | |
| 81513 | <1% | 706 | $54K | |
| 83540 | <1% | 9,194 | $53K | |
| 87340 | <1% | 5,845 | $52K | |
| 87088 | <1% | 13,227 | $50K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,732 | $49K |
| 82746 | <1% | 3,271 | $47K | |
| 77080 | <1% | 288 | $46K | |
| 87536 | <1% | 580 | $44K | |
| 73130 | <1% | 875 | $43K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,589 | $42K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,843 | $41K |
| 87040 | <1% | 12,601 | $40K | |
| 86762 | <1% | 3,006 | $40K | |
| 82043 | <1% | 6,234 | $40K | |
| 72146 | <1% | 166 | $40K | |
| 76380 | <1% | 547 | $39K | |
| 87210 | <1% | 9,656 | $38K | |
| 77065 | Tomosynthesis, mammo | <1% | 428 | $38K |
| 84153 | <1% | 2,005 | $37K | |
| 73502 | <1% | 547 | $37K | |
| 86787 | <1% | 3,072 | $35K | |
| 83655 | <1% | 3,560 | $35K | |
| 0250 | <1% | 7,637 | $35K | |
| 76870 | <1% | 398 | $35K | |
| 82040 | <1% | 9,044 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,633 | $34K |
| 82248 | <1% | 14,000 | $33K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,061 | $32K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 323 | $32K |
| 83721 | <1% | 3,007 | $31K | |
| 82570 | <1% | 5,530 | $31K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 190 | $30K |
| 85652 | <1% | 11,963 | $29K | |
| 90686 | <1% | 2,618 | $29K | |
| 73110 | <1% | 523 | $29K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 725 | $29K |
| 86923 | <1% | 317 | $28K | |
| 84439 | <1% | 3,256 | $28K | |
| 84132 | <1% | 5,932 | $27K | |
| 87481 | <1% | 790 | $27K | |
| 83605 | <1% | 8,026 | $26K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 703 | $26K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,361 | $25K |
| 84165 | <1% | 2,071 | $25K | |
| 84403 | <1% | 914 | $25K | |
| 74018 | <1% | 459 | $24K | |
| 73221 | <1% | 95 | $24K | |
| 82105 | <1% | 1,377 | $24K | |
| 83021 | <1% | 1,343 | $23K | |
| 84100 | <1% | 9,492 | $23K | |
| 70491 | <1% | 108 | $22K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 860 | $22K |
| 83615 | <1% | 4,711 | $21K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,671 | $21K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 269 | $21K |
| 86038 | <1% | 1,945 | $21K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,805 | $21K |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 254 | $21K |
| 84156 | <1% | 5,173 | $20K | |
| 83718 | <1% | 2,491 | $19K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,451 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 162 | $19K |
| 85379 | <1% | 3,158 | $18K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 738 | $18K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 321 | $18K |
| 76881 | <1% | 175 | $17K | |
| 80076 | <1% | 2,059 | $16K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,034 | $16K |
| 85730 | <1% | 3,957 | $16K | |
| 73140 | <1% | 285 | $16K | |
| 82378 | <1% | 830 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 136 | $16K |
| 86704 | <1% | 1,486 | $15K | |
| 84295 | <1% | 3,074 | $15K | |
| 87449 | <1% | 1,379 | $15K | |
| 86765 | <1% | 1,082 | $14K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,059 | $14K |
| 73100 | <1% | 195 | $13K | |
| 82950 | <1% | 2,771 | $12K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 433 | $12K |
| 82465 | <1% | 2,965 | $12K | |
| 78306 | <1% | 31 | $12K | |
| 82784 | <1% | 588 | $12K | |
| 70496 | <1% | 46 | $12K | |
| 87631 | <1% | 221 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 119 | $11K |
| P9021 | Red blood cells, each unit | <1% | 288 | $11K |
| 82077 | <1% | 1,997 | $11K | |
| 80306 | <1% | 1,430 | $11K | |
| 84146 | <1% | 582 | $11K | |
| 72197 | <1% | 24 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,875 | $11K |
| 84550 | <1% | 2,967 | $11K | |
| 83001 | <1% | 557 | $11K | |
| 85014 | <1% | 4,506 | $10K | |
| 86317 | <1% | 786 | $10K | |
| 82550 | <1% | 2,184 | $9K | |
| 72040 | <1% | 191 | $9K | |
| 73590 | <1% | 150 | $9K | |
| J3490 | Unclassified drugs | <1% | 5,072 | $9K |
| 86160 | <1% | 460 | $9K | |
| 71101 | <1% | 78 | $9K | |
| 70498 | <1% | 28 | $8K | |
| 81015 | <1% | 2,222 | $8K | |
| 85046 | <1% | 1,423 | $8K | |
| 85018 | <1% | 2,849 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 84 | $7K |
| Z7502 | <1% | 497 | $7K | |
| 80179 | <1% | 1,200 | $7K | |
| 0710 | <1% | 829 | $7K | |
| 86431 | <1% | 1,150 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,656 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 369 | $6K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 559 | $6K |
| 88342 | <1% | 65 | $6K | |
| 82977 | <1% | 794 | $6K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,538 | $6K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 608 | $6K |
| J1815 | Injection, insulin, per 5 units | <1% | 3,420 | $5K |
| 87324 | <1% | 598 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,585 | $5K |
| 82951 | <1% | 343 | $5K | |
| 0258 | <1% | 3,241 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,545 | $5K |
| 87081 | <1% | 2,190 | $5K | |
| 73070 | <1% | 83 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,668 | $5K |
| 97161 | <1% | 405 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,210 | $4K |
| 86677 | <1% | 528 | $4K | |
| 84134 | <1% | 423 | $4K | |
| 87205 | <1% | 1,789 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,028 | $4K |
| 87186 | <1% | 1,219 | $4K | |
| 82670 | <1% | 123 | $4K | |
| 84480 | <1% | 304 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,381 | $4K |
| 80197 | <1% | 228 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,151 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 231 | $3K |
| 82962 | <1% | 2,293 | $3K | |
| 90656 | <1% | 419 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,735 | $3K |
| 96367 | <1% | 224 | $3K | |
| 90662 | <1% | 297 | $3K | |
| 86225 | <1% | 223 | $3K | |
| 86003 | <1% | 68 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 984 | $3K |
| 86665 | <1% | 171 | $3K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 68 | $3K |
| 73560 | <1% | 48 | $2K | |
| 86364 | <1% | 201 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 789 | $2K |
| 99285 | Emergency room visit (most serious) | <1% | 12 | $2K |
| 82627 | <1% | 80 | $2K | |
| 86360 | <1% | 226 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 648 | $2K |
| 0301 | <1% | 129 | $2K | |
| 77072 | <1% | 16 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,445 | $2K |
| 72070 | <1% | 13 | $2K | |
| 82952 | <1% | 343 | $2K | |
| 86359 | <1% | 226 | $1K | |
| 0370 | <1% | 910 | $1K | |
| 86140 | <1% | 1,529 | $1K | |
| 86664 | <1% | 86 | $1K | |
| 84478 | <1% | 213 | $1K | |
| 73090 | <1% | 29 | $1K | |
| 72050 | <1% | 13 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 848 | $1K |
| 87807 | <1% | 305 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 766 | $1K |
| 87070 | <1% | 410 | $1K | |
| 90715 | <1% | 48 | $953.80 | |
| 73120 | <1% | 13 | $951.36 | |
| 86334 | <1% | 40 | $920.89 | |
| C1769 | Guide wire | <1% | 29 | $859.91 |
| 82805 | <1% | 86 | $824.85 | |
| 86335 | <1% | 12 | $805.00 | |
| 86308 | <1% | 173 | $792.50 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 263 | $729.20 |
| 72081 | <1% | 12 | $725.00 | |
| 84270 | <1% | 27 | $714.73 | |
| 73080 | <1% | 31 | $709.77 | |
| 86769 | <1% | 27 | $670.13 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 53 | $647.21 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 759 | $631.34 |
| 85384 | <1% | 202 | $616.68 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 359 | $561.46 |
| 82150 | <1% | 92 | $557.00 | |
| 83010 | <1% | 44 | $528.91 | |
| 83002 | <1% | 25 | $503.00 | |
| 84145 | <1% | 119 | $421.11 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 31 | $394.54 |
| 80164 | <1% | 38 | $386.58 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 392 | $353.27 |
| 86735 | <1% | 32 | $341.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 475 | $312.62 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 412 | $306.47 |
| 86256 | <1% | 12 | $306.00 | |
| 88304 | <1% | 85 | $300.00 | |
| 86304 | <1% | 13 | $285.39 | |
| 82140 | <1% | 50 | $279.42 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 75 | $272.93 |
| 90688 | <1% | 44 | $267.64 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 188 | $250.61 |
| 80320 | <1% | 385 | $229.80 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $225.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 108 | $223.73 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 133 | $222.83 |
| 80359 | <1% | 104 | $218.85 | |
| 0305 | <1% | 72 | $191.00 | |
| 86708 | <1% | 26 | $183.03 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 131 | $178.36 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 153 | $167.87 |
| 85045 | <1% | 56 | $163.10 | |
| 84155 | <1% | 42 | $162.67 | |
| 74022 | <1% | 26 | $148.07 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 110 | $131.22 |
| 80329 | <1% | 261 | $130.20 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 329 | $125.17 |
| 86709 | <1% | 12 | $123.04 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 49 | $105.50 |
| 83935 | <1% | 29 | $89.82 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 55 | $82.62 |
| 87149 | <1% | 29 | $74.70 | |
| 87517 | <1% | 14 | $74.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 995 | $71.42 |
| 80324 | <1% | 89 | $70.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 119 | $67.23 |
| 83930 | <1% | 18 | $57.75 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 131 | $50.26 |
| 0306 | <1% | 22 | $49.60 | |
| 0320 | <1% | 20 | $49.60 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 61 | $49.60 |
| 0272 | <1% | 74 | $37.25 | |
| 89051 | <1% | 18 | $23.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 25 | $20.82 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 108 | $17.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 21 | $6.35 |
| 3074F | 0% | 31 | $0.00 | |
| 3044F | 0% | 2,814 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 24 | $0.00 |
| 88307 | 0% | 26 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 28 | $0.00 |
| 0171 | Inj, epinephrine (belcher) | 0% | 20 | $0.00 |
| 86255 | 0% | 13 | $0.00 | |
| 3051F | 0% | 129 | $0.00 | |
| 0722 | 0% | 22 | $0.00 | |
| 0300 | 0% | 47 | $0.00 | |
| 0360 | 0% | 22 | $0.00 | |
| 3046F | 0% | 84 | $0.00 | |
| 3078F | 0% | 31 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 28 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 12 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLE, LESLEY (EXECUTIVE DIRECTOR)